Benjamin Levy, MD, Kamel Abou Hussein, MD, Nicholas Hornstein, MD, PhD, and Nicole Balmaceda, MD, compare how PD-L1, HER2, BRAF, KRAS, and TROP2 are tested, scored, and used to guide treatment in lung, breast, and gastrointestinal cancers, including liquid biopsy and retesting at progression.
Benjamin Levy, MD, opens a discussion with Kamel Abou Hussein, MD, Nicholas Hornstein, MD, PhD, and Nicole Balmaceda, MD, on how biomarkers differ across tumor types, then explains how programmed death-ligand 1 (PD-L1) guides treatment in non-small cell lung cancer.
Kamel Abou Hussein, MD, explains why breast oncologists score programmed death-ligand 1 (PD-L1) using the combined positive score (CPS) rather than the tumor proportion score, since PD-L1 expression in breast cancer sits mainly in the immune microenvironment
